BidaskClub upgraded shares of Cellectis (NASDAQ:CLLS) from a sell rating to a hold rating in a research note published on Saturday.
Several other research firms have also recently issued reports on CLLS. Zacks Investment Research cut shares of Cellectis from a buy rating to a hold rating in a research report on Tuesday, July 10th. Oppenheimer boosted their price objective on shares of Cellectis from $40.00 to $44.00 and gave the company an outperform rating in a research report on Tuesday, June 12th. Barclays started coverage on shares of Cellectis in a research report on Monday, July 16th. They issued an overweight rating and a $50.00 price objective for the company. Finally, ValuEngine raised shares of Cellectis from a hold rating to a buy rating in a research report on Tuesday, September 18th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $49.20.
Cellectis stock opened at $27.50 on Friday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.89 and a beta of 1.84. Cellectis has a 1 year low of $22.62 and a 1 year high of $38.85.
Several institutional investors and hedge funds have recently made changes to their positions in CLLS. FMR LLC lifted its position in shares of Cellectis by 18.0% in the 2nd quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock worth $119,949,000 after purchasing an additional 647,164 shares during the period. Nexthera Capital LP purchased a new stake in shares of Cellectis in the 1st quarter worth approximately $10,485,000. BlackRock Inc. lifted its position in shares of Cellectis by 259.7% in the 2nd quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock worth $12,552,000 after purchasing an additional 320,340 shares during the period. Laurion Capital Management LP purchased a new stake in shares of Cellectis in the 2nd quarter worth approximately $5,658,000. Finally, ARK Investment Management LLC lifted its position in shares of Cellectis by 178.8% in the 2nd quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock worth $6,910,000 after purchasing an additional 156,666 shares during the period. 27.10% of the stock is owned by hedge funds and other institutional investors.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Story: Conference Calls and Individual Investors
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.